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Abstract
Background: Castration resistant prostate cancer (CRPC) develops as a consequence of hormone therapies used to 
deplete androgens in advanced prostate cancer patients. CRPC cells are able to grow in a low androgen environment 
and this is associated with anomalous activity of their endogenous androgen receptor (AR) despite the low systemic 
androgen levels in the patients. Therefore, the reactivated tumor cell androgen signaling pathway is thought to 
provide a target for control of CRPC. Previously, we reported that Hedgehog (Hh) signaling was conditionally activated 
by androgen deprivation in androgen sensitive prostate cancer cells and here we studied the potential for cross-talk 
between Hh and androgen signaling activities in androgen deprived and androgen independent (AI) prostate cancer 
cells.
Results: Treatment of a variety of androgen-deprived or AI prostate cancer cells with the Hh inhibitor, cyclopamine, 
resulted in dose-dependent modulation of the expression of genes that are regulated by androgen. The effect of 
cyclopamine on endogenous androgen-regulated gene expression in androgen deprived and AI prostate cancer cells 
was consistent with the suppressive effects of cyclopamine on the expression of a reporter gene (luciferase) from two 
different androgen-dependent promoters. Similarly, reduction of smoothened (Smo) expression with siRNA co-
suppressed expression of androgen-inducible KLK2 and KLK3 in androgen deprived cells without affecting the 
expression of androgen receptor (AR) mRNA or protein. Cyclopamine also prevented the outgrowth of AI cells from 
androgen growth-dependent parental LNCaP cells and suppressed the growth of an overt AI-LNCaP variant whereas 
supplemental androgen (R1881) restored growth to the AI cells in the presence of cyclopamine. Conversely, 
overexpression of Gli1 or Gli2 in LNCaP cells enhanced AR-specific gene expression in the absence of androgen. 
Overexpressed Gli1/Gli2 also enabled parental LNCaP cells to grow in androgen depleted medium. AR protein co-
immunoprecipitates with Gli2 protein from transfected 293T cell lysates.
Conclusions: Collectively, our results indicate that Hh/Gli signaling supports androgen signaling and AI growth in 
prostate cancer cells in a low androgen environment. The finding that Gli2 co-immunoprecipitates with AR protein 
suggests that an interaction between these proteins might be the basis for Hedgehog/Gli support of androgen 
signaling under this condition.
Background
When detected in the advanced stage, prostate cancer
patients are treated with hormone therapies that reduce
systemic androgen levels [1-3]. This action palliates the
symptoms of metastases, induces regression of metastatic
lesions and slows prostate tumor growth [4]. Over time,
however, the cancer can recur in a castration resistant
form (CRPC) that continues to grow despite the ability of
hormone therapy to maintain systemic androgens at cas-
trate levels and deaths from prostate cancer are inevitably
associated with complications from this form of disease
[5]. Progression of prostate cancer to CRPC appears to
involve a reactivation of androgen signaling in the cancer
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cells [6-8] and a variety of mechanisms may account for
residual androgen signaling in a low androgen environ-
ment. These include expression of variant forms of
androgen receptor (AR) that are transcriptionally active
without ligand [9,10], acquisition of an ability to endoge-
nously synthesize androgens by the tumor cells them-
selves [11,12] or activation of aberrant AR transcriptional
activity through cross-talk with alternate signaling path-
ways [6,13]. While all of these mechanisms are of interest
from a scientific viewpoint, the ones that are readily tar-
getable by drugs are the most clinically imperative as they
offer an opportunity to test novel therapies to treat a dis-
ease that will kill almost 28,000 men in the United States
this year. Recent reports that Abiraterone, an inhibitor of
androgen biosynthesis, has clinical effects against castra-
tion resistant prostate cancer, reflects a potential treat-
ment advance that might target tumor cell androgen
biosynthesis [14]. Here we describe findings that suggest
that inhibitors of the Hedgehog/Gli signaling pathway,
currently in clinical testing for a variety of cancers, might
also have a role for the treatment of castration resistant
prostate cancer due to an ability to suppress reactivated
androgen signaling in tumor cells.
Hedgehog (Hh) is best known for its role in tissue pat-
terning and morphogenesis during embryonic develop-
ment [15-18]. In the developmental situation, Hh is a
ligand-driven process in which a ligand (referred to as a
Hedgehog) engages the Patched 1 (Ptch) receptor on the
cell surface and this relieves repression of Smoothened
(Smo), a member of the extended G protein coupled
r e c e p t o r  f a m i l y  [ 1 8 ] .  S m o ,  w h e n  a c t i v a t e d ,  t h e n  a c t s
downstream to alter the processing and intracellular
localization of Gli transcription factors and to increase
Gli-mediated transcriptional activity. The plant-derived
alkaloid, cyclopamine, is a prototype for a drug that
antagonizes the Hh signaling process [19]. Cyclopamine
antagonizes Smo activation and this action explains the
teratogenic effects of this drug when it is ingested during
pregnancy [20,21].
Aside from its role in development, Hh signaling also
supports stem cells in adult tissues [22-24]. However,
chronically hyperactive Hh/Gli signaling in adult tissues
can be oncogenic, especially for the skin or brain [25,26].
Basal cell carcinoma of the skin and medulloblastoma are
models for human Hh-mediated oncogenesis [27]. The
aberrant Hh activity in these tumors can result from a
loss of the Ptch gene or its function [28,29], mutations in
Smo [30] or SuFu [31] that activate endogenous Hh sig-
naling or cryptic overexpression of Gli proteins in tumor
cells. For prostate cancer, the question as to whether Hh/
Gli signaling plays any role is controversial. Although
cyclopamine treatment or Gli knockdown suppresses the
in vitro growth of prostate cancer cell lines or xenograft
tumor growth in mice [32-34], the commonly used pros-
tate cancer cell lines show little, if any, evidence for active
canonical Hh signaling activity when they are grown in
standard culture conditions [35,36]. For the androgen-
growth dependent LNCaP prostate cancer cells and its
variants, C4-2 and C4-2B, however, the situation was
found to be changed by chronic exposure of these cells to
androgen depleted medium. Androgen deprivation
highly upregulated the expression and secretion of Hh
ligands and increased endogenous expression of Hh/Gli
target genes in these cells [37]. The clinical relevance of
this observation is supported by the observation that Hh
ligand production was found to be increased in prostate
tumors by neoadjuvant hormone treatment [38]. Since
cyclopamine suppresses the expression of Hh target
genes in androgen-deprived LNCaP cells (37), this also
suggests that active Hh/Gli signaling activity is awakened
by growth under androgen deprived conditions. Others
have observed that the high basal expression of Hh/Gli
t a r g e t  g e n e s  i n  a n d r o g e n  i n d e p e n d e n t  ( A I )  v a r i a n t s  o f
LNCaP was reduced by cyclopamine [39] and, collec-
tively, the outcomes of these studies imply that Hh signal-
ing in LNCaP cells is restricted to the androgen deprived
or AI state. The question remains as to whether active Hh
signaling has any biological consequences for the andro-
gen deprived or AI prostate cancer cell. Here we show
that, by manipulating the activity of canonical Hh signal-
ing in androgen deprived or AI prostate cancer cells, we
also affected the expression of androgen regulated genes
and the ability of these cells to grow in the absence of
androgen. Our results indicate that Hh/Gli signaling
activity supports androgen signaling and AI growth in
prostate cancer under low/no androgen conditions. Fur-
thermore, we report that Gli2 protein can bind to AR and
this interaction might define the point of cross-talk
between the two signaling pathways.
Results and Discussion
Previously we reported evidence for conditional activa-
tion of canonical Hh signaling in androgen sensitive
human prostate cancer cells by culture in an androgen
depleted conditions [37]. Here, we used androgen sensi-
tive parental LNCaP cells, other derivatives of LNCaP
that are less dependent on androgens for growth (C4-2,
LN3, LNCaP-AI) or androgen responsive VCaP cells that
are unrelated to LNCaP, to study the effects of Hh signal-
ing manipulation on the expression of androgen regu-
lated genes in these cells. The LNCaP-AI variant cells
that we used were independently isolated in our lab fol-
lowing long-term (> 1 year) culture of parental LNCaP
cells in androgen depleted medium. These cells downreg-
ulate basal expression of Ptch1 when treated with cyclo-
pamine (Additional file 1, Figure S1) so they appear to
have basal-active Hh signaling activity similar to other AI
derivatives of LNCaP that were previously described (39).Chen et al. Molecular Cancer 2010, 9:89
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Initially, we tested the effects of the classic Hh inhibitor
drug, cyclopamine on androgen regulated gene expres-
sion. All experiments were done using a medium that was
depleted for androgens (phenol red-free RPMI with char-
coal-stripped FBS) that could be re-supplemented with
androgen (R1881) to mimic androgen-stimulated condi-
tions. For parental LNCaP cells grown in androgen sup-
plemented medium (+R1881), the presence of
cyclopamine had no significant effects on the expression
of four model androgen-regulated genes; KLK2, KLK3
[PSA] and PGC (androgen-inducible), or SHH that is
repressed by androgen (Figure 1A). However, when these
c e l l s  w e r e  s w i t c h e d  t o  a n d r o g e n  d e p l e t e d  m e d i u m  ( -
R1881) for 3 days, cyclopamine treatment had a distinct
dose-dependent effect that further suppressed expression
of KLK2, KLK3 and PGC and further increased expres-
sion of SHH (Figure 1A). Likewise, cyclopamine signifi-
cantly downregulated expression of KLK2, KLK3 and
PGC in the LNCaP-AI cells that are normally propagated
in androgen-free medium, and it upregulated the expres-
sion of SHH in these cells (Figure 1A). Cyclopamine also
suppressed the expression of KLK2 and KLK3 in VCaP,
LN3 or C4-2B cells grown in androgen depleted medium
for 3 days (Additional file 1, Figure S2), so the effects of
cyclopamine on androgen regulated genes were not lim-
ited to LNCaP or its derivatives. We also tested whether a
more water-soluble cyclopamine derivative, KAAD-
cyclopamine, had a similar effect and found that this drug
(at 0.5 or 1 μM) was as effective in reducing KLK2/3 and
PGC expression in androgen-deprived LNCaP or
LNCaP-AI cells as the 5 or 10 μM dose of cyclopamine
(Additional file 1, Figure S3). Finally, we found that cyclo-
pamine also significantly diminished the expression of a
reporter gene (luciferase) from either of two androgen
dependent promoters (Probasin [PRB] or PGC) in
LNCaP or LNCaP AI cells in androgen depleted medium
(Figure 1B) in a dose dependent manner. As for endoge-
nous androgen-regulated genes, cyclopamine did not
affect the expression of the reporter when cells were cul-
tured in medium supplemented with 10 pM R1881 (data
not shown).
Cyclopamine represses Hh signaling through its ability
to antagonize Smo activation so we also tested whether
Smo expression knockdown (using siRNA) could mimic
the effects of cyclopamine with regards to suppression of
androgen-inducible gene expression. LNCaP cells were
transfected either with control (non-targeting) siRNA or
with siRNA targeting AR or Smo and were thereafter
maintained in androgen-depleted medium. AR siRNA
selectively reduced expression of AR mRNA and protein
(Figures 2A, C) but did not reduce the expression of Smo.
Likewise, Smo siRNA reduced Smo mRNA levels but did
not affect expression of AR mRNA or protein (Figure 2C).
However, both AR and Smo siRNAs similarly reduced
expression of KLK2 and KLK3 (Figure 2A). Further
assessment of the effects of AR or Smo siRNA on expres-
sion of a luciferase reporter from either a Gli- or andro-
gen-responsive promoter showed that AR knockdown
selectively reduced expression of the androgen reporter
but did not affect expression of the Gli reporter (Figure
2B). In contrast, Smo knockdown significantly reduced
expression of both the Gli and androgen reporters (Figure
2B) in androgen deprived LNCaP cells. In summary, the
above data shows that suppression of Hh signaling with a
Smo antagonist, cyclopamine, or by reduction of Smo
expression itself, suppresses expression of androgen
inducible genes and induces expression of androgen
repressed genes, but only when these human prostate
cancer cells were cultured in a medium lacking androgen.
The fact that Smo knockdown reduced expression of
androgen regulated genes but did not affect expression of
AR mRNA or protein suggests that some aspect of Hh
signaling regulates the activity of the AR rather than its
expression.
Since cyclopamine suppressed residual/reactivated
androgen gene expression in androgen deprived and AI
prostate cancer cells, we also sought evidence that this
effect had biological consequences relevant to AI growth.
First, we tested whether the presence of cyclopamine
might prevent the development of AI cells from parental
LNCaP cells chronically maintained in androgen depleted
medium. LNCaP cells were seeded onto 10 plates at low
density and then 5 plates each were switched to androgen
depleted medium supplemented with vehicle (EtOH) or
with 5 μM cyclopamine. The media were changed every 3
days. Within 2 months, cell numbers in the cyclopamine-
treated cultures were significantly reduced compared to
vehicle-treated cultures and most surviving cells in the
cyclopamine-treated cultures were shrunken with opti-
cally dense nuclei that contrasted with the neuroendo-
crine cell-like appearance of cells in vehicle-treated
cultures (Figure 3A). By the third month, cyclopamine-
treated cultures had less than 1% of the cells of vehicle-
treated cultures and all remaining cells showed the pres-
ence of the optically dense nuclei. No cells remained on
cyclopamine-treated plates by 4 months of culture but
the cells in the vehicle-treated cultures were increasing in
n u m b e r s  b y  t h i s  t i m e  a n d  t h e s e  c u l t u r e s  g a v e  r i s e  t o
growing lawns of cells by 6 months that typify AI growth.
For overt LNCaP-AI cells, we found that treatment with 5
μM cyclopamine significantly inhibited their growth over
a 10 day period (Figure 3B) but when cyclopamine treat-
ment was accompanied by supplemental androgen (10
pM R1881), the growth rate of these cells was no different
than vehicle treated cells. This indicates that the presence
of androgen can overcome the growth-inhibiting effects
of cyclopamine on overt AI cells.Chen et al. Molecular Cancer 2010, 9:89
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F i n a l l y ,  w e  s o u g h t  t o  t e s t  w h e t h e r  o v e r e x p r e s s i o n  o f
Gli1 or Gli2, transcription factors that lie at the endpoint
of the Hh signaling process, might act oppositely to Smo
antagonism/inhibition to increase androgen signaling or
AI growth when LNCaP cells were grown in androgen
free medium. Parental LNCaP cells were transduced with
a Gli1- or Gli2- (Gli2ΔN) expressing lentivirus and these
cells were compared to control cells transduced with
empty virus to determine the effects of Gli overexpres-
sion on androgen regulated gene expression and cell
growth in androgen depleted medium. The Gli overex-
pressing variants of LNCaP were also found to express
significantly higher levels of KLK2 or KLK3 when com-
pared to control (vector transduced) cells in androgen
Figure 1 Effect of cyclopamine on androgen signaling in LNCaP cells. (A) Real time qPCR was used to measure relative expression of KLK3, KLK2, 
PGC or SHH mRNA in androgen-supplemented (+R1881) or androgen deprived (-R1881) LNCaP or in LNCaP-AI cells (-R1881) in the presence of vehicle 
(EtOH) or with 5 or 10 μM cyclopamine (Cyc-5, Cyc-10) (also see Additional file 2, Table S2). (B) LNCaP or LNCaP-AI cells were infected with probasin 
(PRB) or PGC promoter reporter vectors along with a CMV-GFP reference reporter and were cultured in androgen depleted medium with vehicle 
(EtOH) or with 5 or 10 μM cyclopamine (Cyc-5 or Cyc-10) for 72 hrs. Cell extracts were assayed for luciferase that was normalized by GFP intensity. Bars 
represent the means of triplicate experiments ± S.E. (* = P < 0.05 compared to vehicle control; ** = P < 0.05 between 5 and 10 μM cyclopamine treat-
ment groups).
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Figure 2 Smo knockdown affects androgen responsive gene expression in androgen-deprived LNCaP cells. (A) LNCaP cells were transfected 
with control (Ctrl) siRNA, AR or Smo siRNA and grown in androgen-depleted medium for 72 hrs. RNAs were extracted and assayed by real-time qPCR 
for expression of AR, Smo, KLK2 or KLK3. Bars represent the means of three experiments ± S.E. (* = P < 0.05 compared to control siRNA). (B) Cells trans-
fected with siRNA were infected with a Gli or Probasin (PRB) FF luciferase reporter lentivirus along with a CMV-GFP lentivirus control reporter and were 
switched to androgen-depleted medium for 72 hrs. Cell extracts were quantified for luciferase activity that was normalized by GFP intensity. Bars rep-
resent the means of triplicate experiments ± S.E. (* = P < 0.05 compared to control siRNA). (C) Western blot shows effects of siRNA on expression of 
AR protein in cell lysates.
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Figure 3 Cyclopamine prevents the development of AI prostate cancer cell growth and suppresses the growth of LNCaP-AI cells. (A) Phase 
contrast photomicrographs (40×) of LNCaP cells cultured for 60 days in androgen depleted medium (CS-FBS) supplemented with vehicle (EtOH) or 5 
μM cyclopamine (Cyclo). Cell numbers in cyclopamine are greatly reduced and cells have optically dense, fragmented nuclei. (B) LNCaP-AI cells grown 
in androgen-depleted medium (CS-FBS) supplemented with vehicle (EtOH) or 5 μM cyclopamine. Cell numbers were counted at various days as in-
dicated. Points represent the means of triplicate cultures ± S.E.
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depleted medium (Figure 4A). Gli1 or Gli2 overexpress-
ing LNCaP cells also expressed significantly higher levels
of luciferase reporter from both AR and Gli dependent
promoters compared to control cells (Figure 4B). Despite
higher basal expression of androgen regulated genes, the
Gli transduced cells expressed AR protein at equivalent
levels to the control cells (Figure 4C) so here again, these
e f f e c t s  a p p e a r  t o  b e  i n d e p e n d e n t  o f  c h a n g e s  i n  A R
expression. The Gli transduced LNCaP cells also showed
significant increased growth in androgen depleted
medium compared to the control cells (Figure 4D),
though Gli2 cells appeared to be more robust than Gli1 in
Figure 4 Gli overexpression affects androgen regulated gene expression in androgen-deprived LNCaP cells. (A) RNAs from control (Vec) or 
Gli1 or Gli2 (Gli2ΔN) overexpressing LNCaP cells cultured in androgen-depleted medium for 72 hrs were assayed by real-time qPCR for expression of 
Gli1, Gli2, KLK2 and KLK3. Bars represent the means of three experiments ± S.E. (* = P < 0.05 compared to vector control). (B) Cells were infected with 
a Gli or Probasin (PRB) reporter with CMV-GFP and switched to androgen-depleted medium for 72 hrs. Cell extracts were quantified for luciferase that 
was normalized by GFP intensity. Bars represent the means of triplicate experiments ± S.E. (* = P < 0.05 compared to vector control). (C) Western blot 
shows that Gli1 or Gli2 overexpression does not affect expression of AR protein. (D) Gli overexpression enables androgen independent cell growth. 
Control (Vec) or Gli1 or Gli2 (Gli2ΔN) overexpressing LNCaP cells were cultured in androgen depleted medium for 12 days and growth was measured 
by WST-1 assay and compared to Day 0. Bars represent the means of three experiments ± S.E. (* = P < 0.05 compared to vector control).
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this regard. Regardless of this differential hierarchy, this
data shows that Gli function supports androgen regulated
gene expression in a low androgen environment as well as
AI growth.
The evidence that Gli1 or Gli2 overexpression upregu-
lates androgen inducible gene expression and AI growth
of androgen deprived LNCaP cells without affecting AR
expression suggests that some function of the Gli pro-
teins may support AR transcriptional activity in a low
androgen environment. We tested for some potential
direct interaction between these Gli and AR proteins in
co-immunoprecipitation experiments. Human 293FT
cells were transfected with an expression plasmid for full-
length human AR, myc-tagged Gli2 or a combination of
these plasmids. Forty-eight hrs later, extracts from the
cells were immunoprecipitated with anti-AR or anti-myc
antibody and the immunoprecipitates (IPs) were analyzed
by Western blot for the presence of AR or myc-tagged
Gli2. When the Western blot was probed with anti-AR,
w e  f o u n d  t h a t  A R  c o - i m m u n o p r e c i p i t a t e d  w i t h  m y c -
tagged Gli2 only in extracts from cells co-transfected
with both plasmids (Figure 5). Similarly, myc-tagged Gli2
was co-immunoprecipitated in the AR IPs from extracts
of cells co-transfected with both plasmids (Figure 5). This
apparent interaction between Gli2 and AR in the 293FT
cells was not diminished by supplementation with 1 nM
R1881.
Here we provided evidence that aspects of the canoni-
cal Hh signaling pathway can play a role in supporting
residual/reactivated androgen signaling in androgen
deprived and AI prostate cancer cells and this finding has
important implications with regards to both the mecha-
nistic basis for AI growth in the castration resistant pros-
tate cell and for treatment strategies for CRPC in
patients. Smo inactivation by cyclopamine, a cyclo-
pamine variant drug (KAAD-cyclopamine) or reduction
in Smo expression by siRNA downregulated androgen
inducible genes in androgen deprived and AI prostate
cancer cells and these findings suggest that some action
of Smo might be important for reactivation of androgen
signaling under low androgen conditions. The effects of
cyclopamine on androgen regulated genes was common
to several types of human prostate cancer cell lines grown
under androgen deprived conditions so the effect was not
limited to LNCaP cells and derivatives. Cyclopamine also
suppressed expression of reporter genes from two differ-
ent androgen responsive promoters in LNCaP cells in
androgen depleted medium and these findings support
the idea that Smo activity supports AR-mediated tran-
scriptional activity in the androgen deprived state. Finally,
the modulatory effects of cyclopamine on AR regulated
gene expression were consistent with the effect of this
drug on AI growth. Chronic cyclopamine treatment pre-
vented the development of androgen growth independent
cells from parental androgen growth-dependent LNCaP
cells and significantly inhibited the growth of an overt AI
variant of LNCaP. The cyclopamine-mediated growth
suppression was reversed by returning a low level of
androgen to the cells, providing further evidence that
effects of cyclopamine on development and growth of AI
cells are based upon cyclopamines' actions on residual
androgen signaling.
Smo action ultimately drives transcription by Gli family
proteins so we also tested whether exogenous expression
of active Gli had opposite effects of cyclopamine or Smo
reduction. Here, our findings that Gli1 or Gli2 overex-
pression enhanced androgen regulated gene expression in
androgen depleted medium and enabled AI growth for
androgen growth-dependent cells strongly argues that
the active Gli proteins resulting from Hh signaling play
the most critical role in Hh-support of residual/reacti-
vated androgen signaling regulation. Although the Gli2
overexpressing LNCaP cells exhibited more robust
androgen independent growth than the Gli1 overexpress-
ing cells, it is not possible to rank the effectiveness of the
Gli proteins on growth control from this study since the
cells may be expressing different amounts of transcrip-
tionally active Gli protein. However, the recent report
that Gli2 protein was abundantly expressed in tumor cells
Figure 5 Co-immunoprecipitation of AR with Gli2 protein. Lysates 
of cells (293FT) transfected with AR, myc-tagged Gli2 (Myc-Gli2ΔN) or 
both for 48 hrs (under androgen-supplemented [R1881] or depleted 
[CS-FBS] conditions) were immunoprecipitated with α-AR or α-myc an-
tibody. IPs or lysates were electrophoresed and blotted. The Western 
blot (WB) was probed with α-AR or α-myc antibody as indicated.
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from patients with AI (CRPC) prostate cancer [40] does
provide further support for the idea that Gli2 protein
e xpression might ha ve a specific role in AI cancer cell
growth in CRPC patients and Gli2 may be the preferred
target for CRPC treatments.
With regards to the potential mechanism(s) through
which Hh/Gli cross-talks to the androgen signaling path-
way, it does not appear to involve changes in the expres-
sion of AR mRNA or protein as this was not affected by
cyclopamine, Smo knockdown or Gli overexpression.
However, the finding that Gli2 and AR proteins co-immu-
noprecipitate when they were co-expressed in 293T cells
does suggest that Gli2 might directly interact with AR to
influence the expression of AR target genes in the same
manner that other co-activator proteins support AR
function [41]. Previously Gli2 was shown capable of bind-
ing to CREB or to Zic family transcription factor proteins
[42,43] so this finding extends the potential repertoire of
transcription factors capable of interacting with Gli2. It is
of further interest that the interaction between AR and
Gli2 proteins was not diminished by androgen supple-
mentation. Therefore, the lack of effects of cyclopamine
on androgen regulated gene expression in androgen sup-
plemented LNCaP cells might be due to some additional
role of other upstream elements of the Hh signaling path-
way that are only manifest in androgen depleted cells.
Additionally, we must consider the possibility that Hh/Gli
signaling is involved in the endogenous production of
androgen (intracrine androgen biosynthesis) that is
reportedly associated with AI prostate cancer cells [11],
especially since Hh signaling is required for steroidogen-
sis in the testis and for androgen production by other
types of cells [44,45]. This is an aspect that we will test for
in future experiments.
Regardless of the mechanism(s) involved, the outcome
of this research suggests that Hh/Gli inhibitors offer a
specific means to target reactivated androgen signaling in
CRPC and to test the idea that inhibition of anomalous
androgen signaling in CRPC cells has therapeutic benefit
for patients. Although cyclopamine is difficult to use as a
therapeutic agent, several pharmaceutical companies are
in the process of developing similar drugs that are easier
to use in the clinical setting and some of these drugs are
through Phase I testing [46]. Therefore, translation of
these experimental studies to patients should be able to
proceed fairly rapidly. Alternatively, there are non-
canonical signaling pathways that increase Gli activity in
cancer cells [47] so a clinical focus on Smo antagonists
m a y not  be  s ufficie n t t o deal  wit h a ll  f o rm s of  CRPC.
Reports of small molecular inhibitors of Hh/Gli signaling
that act independently of Smo antagonism [48], suggests
that Hh/Gli signaling provides a rich array of targets for
the development of more effective treatments for CRPC.
Conclusions
Modulation of Hh signaling in prostate cancer cells by
reduction of Smo expression or activity or by overexpres-
sion of active Gli proteins affected androgen signaling
and the expression of androgen regulated genes in these
cells but only when they were cultured in a low androgen
medium. The effects of Hh modulation on androgen reg-
ulated gene expression in prostate cancer cells were con-
sistent with the coordinate effects on AI cancer cell
development and growth in low androgen medium but
these effects were reversed by the presence of androgens.
Since we have found that Gli2 protein, at least, interacts
with the AR protein, the mechanism through which Hh
signaling affects AR-dependent gene expression and AI
cell growth may involve a direct interaction of AR with
Gli proteins.
Methods
Cells and Culture
Human prostate carcinoma cell lines LNCaP and VCaP
were obtained from the ATCC (Manassas, V A). LNCaP
variants, LN3 or C4-2B were obtained from Curtis Pett-
away, M.D. Anderson Cancer Center (Houston, TX) or
ViroMed Laboratories (Minnetonka, MN), respectively.
The LNCaP-AI variant was derived from parental LNCaP
cells after more than one year growth in androgen-
depleted medium. Cells were maintained in RPMI-1640
medium with 10% fetal bovine serum (FBS) or switched
to phenol red-free RPMI-1640 with 10% charcoal-
stripped FBS (CS-FBS) for androgen-depleted conditions
as previously described (37). The 293FT cells were
obtained from Invitrogen, Inc. (Carlsbad, CA) and were
maintained in DMEM with 10% FBS. Synthetic androgen,
R1881 (methyltrienolone), was obtained from PerkinEl-
mer Life Sciences (Boston, MA) and was supplemented
to androgen-depleted medium at 10 pM where indicated.
Cyclopamine was obtained from Enzo Life Sciences, Intl.
(Plymouth Meeting, PA) and KAAD-cyclopamine from
Toronto Research Chemicals Inc. (North York, ON, Can-
ada). Cultured cells were imaged by a Leica DMIRE2
inverted microscope (Leica Microsystems Inc., Bannock-
burn, IL).
Generation of LNCaP Lines Stably Expressing Gli 
Transcription Factors
The ViraPower™ Lentiviral Expression System (Invitro-
gen) was used for generating replication-incompetent
lentiviruses expressing recombinant human Gli1 or
Gli2ΔN. All procedures were performed according to the
manufacturers' protocols with modifications: 1) cDNAs
encoding the full-length human Gli1 and the N-terminal-
truncated human Gli2 were cloned from the plasmid GLI
K12 [49] and pCS2-MT GLI2(ΔN) [50] (Addgene, Cam-Chen et al. Molecular Cancer 2010, 9:89
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bridge, MA) into pLenti6 (Invitrogen); 2) For production
of lentivirus in 293FT cells, 3 μg of pLenti6-Gli1, pLenti6-
Gli2ΔN or pLenti6-Vec (empty vector control) were
mixed with 9 μg of ViraPower Packaging Mix, and 36 μl of
Lipofectamine-2000 (Invitrogen). The mixture was
applied to 2 × 106 293FT cells in medium overnight.
Transfection medium was removed and fresh medium
was added for another 72 hours. Lentivirus containing
medium was collected and filtered and used for infec-
tions; 3) LNCaP cells were seeded at 50% confluence
overnight in preparation for viral transduction. Virus
supernatants were added (diluted 1:5 with medium) and
48 hrs later, blasticidin was added at a concentration of 10
μg/ml for selection. Selection was carried out for 2-3
weeks and ~200 colonies were obtained and pooled as
stably-expressing sublines, LNCaP-Vec, LNCaP-Gli1, or
LNCaP-Gli2ΔN.
RNA Isolation and Reverse Transcription - Real-Time PCR 
Assays (RT-qPCR)
RNA was isolated from cells using the RNeasy Mini Kit
with RNase-Free DNase digestion (QIAGEN, Valencia,
CA). Reverse transcription was carried out using Super-
Script® III First-Strand Synthesis SuperMix for qRT-PCR
(Invitrogen) per the supplier's protocol. Real-time PCR
was performed on an ABI 7900HT detection system
(Applied Biosystems, Foster City, CA) using RT2 SYBR
Green/ROX qPCR Master Mix (SABiosciences, Freder-
ick, MD) according to the manufacturer's protocol. The
thermal cycling conditions were as previously described
(37). The message number of glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was used as the reference
for calculating specific gene messages. The sequences of
qPCR primers used are listed in Additional file 2, T able
S1.
Promoter activity assays
Firefly luciferase reporter vectors under the control of a
promoter containing eight repeats of the Gli consensus
sequence (pLLRM-GLI-Luc) was generated by sub-clon-
ing the GLI-responsive promoter fragment from pGL3B/
8XGliBS-lc-luc (JHU-73, ATCC) into a lentiviral
luciferase reporter vector, pLLRM. Reporter vectors with
rat probasin (PRB) or human Pepsinogen C (PGC) gene
promoters and a reference construct expressing GFP
under the CMV promoter (pLLCM-GFP) were prepared
(Ohouo et al., in preparation) and were used to produce
lentiviruses in 293FT cells as described above. Cells were
lysed 72 hrs after infection with Passive Lysis Buffer (Pro-
mega, Madison, WI) and lysates were analyzed for
luciferase activity with the 20/20 n Single Tube Lumi-
nometer (Turner Biosystems Inc., Sunnyvale CA) using a
Luciferase Assay Kit (Promega). GFP intensity was mea-
sured by the BMG FLUOstar Optima plate reader (Imgen
Technologies, Alexandria, VA) and used to normalize
viral-infection efficiency.
Silencing AR and Smo expression in LNCaP cells by siRNA 
transfection
The siRNAs specifically targeting human Smo, human AR
and control siRNA were purchased from QIAGEN.
LNCaP cells were seeded at 70% confluence. siRNAs (40
pM) were mixed with 3 μl of SiLentFect Lipid Reagent for
RNAi (Bio-Rad, Hercules, CA) in Opti-MEM I (Invitro-
gen) for 20 min and this was added to each well in 1.5 ml
of medium. Medium was changed 24 hrs after transfec-
tion and 72 hrs later, cells were collected for total RNA
isolation or lysed in RIPA buffer for Western blot analysis.
Western blot analysis
Cells lysates were assayed for protein and equal amounts
of protein were analyzed by Western blot with appropri-
ate antibodies. Each membrane was re-blotted with
GAPDH antibody as a control for protein loading. Anti-
bodies were used at the following dilutions: GAPDH at
1:5,000, AR at 1:10,000, and Myc at 1:5,000. Appropriate
secondary antibodies conjugated to horseradish peroxi-
dase were used at 1:10,000, and blots were developed by
enhanced chemilluminescence reagent (Thermo Fisher
Scientific Inc., Rockford, IL). Antibodies to GAPDH or
AR receptor (H-280) were from Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, CA). The monoclonal antibody to
Myc-tag (4A6) was purchased from Millipore (Billerica,
MA).
Cell Proliferation WST-1 Assay
Cells were seeded onto a 96-well plate at a density of
5,000 cells/well in CS-FBS media and were maintained
for indicated days (media refreshed every 3 days). At
appropriate times, 10 μl WST-1 (Roche, Indianapolis, IN)
was added to each well and plates were kept at 37°C for
two hrs. Color intensity was read at 450 nm (reference
wavelength 650 nm) on the SpectraMax M2 microplate
reader (Molecular Devices, Sunnyvale, CA)
Co-immunoprecipitation of AR and Gli2 in 293FT cells
Transfection of 293FT cells (2 × 106 cells) with AR or
Gli2ΔN plasmids was carried out with Lipofectamine-
2000. Cells were lysed in a 1% Triton X-100 lysis buffer
with protease inhibitor cocktail (Roche) 48 hrs later. Ali-
quots of extract containing equal amounts of protein
were precipitated at 4°C overnight with 50 μl Dynabeads
Protein G (Invitrogen) pre-bound with 5 μg appropriate
antibodies. Beads were washed by lysis buffer four times
and immunoprecipitated proteins were eluted in 2× SDS
sample buffer. The elutant was split into equivalent por-
tions and blotted onto 2 membranes for Western blot
analysis.Chen et al. Molecular Cancer 2010, 9:89
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Statistical Analysis
Expression levels determined using RT-qPCR and pro-
moter activity assay data were compared by comparison
of the "means", wherein the data graphed or listed in the
table represent the Means ± Standard Error (S.E.). The
Student t-Test (one-tailed, equal variance) was employed
for assessing statistical difference (defined as when p <
0.05) between data groups.
List of Abbreviations Used
AI: Androgen Independent (Growth); AR: Androgen
Receptor; CRPC: Castration Resistant Prostate Cancer;
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